Company Information
Corporate Profile
Corporate Profile
| Company Name | Innovacell Inc. |
|---|---|
| Representatives |
|
| Location |
MEGURO VILLA GARDEN 5F 3-5-11 Kamiosaki, Shinagawa-ku, Tokyo 141-0021 |
| Date of Establishment | January 5, 2021 |
| Business Activities | Development and manufacturing of regenerative medicine products targeting fecal incontinence and urinary incontinence diseases. |
| Subsidiary |
Company History
Innovacell Biotechnologie AG, the predecessor of our group company (now known as Innovacell GmbH), is a cell therapy startup that spun out from the Medical University of Innsbruck in Austria. Our company was established as a subsidiary of this Austrian firm and was founded in Japan in January 2021
History of our predecessor company (now known as Innovacell GmbH) leading up to the establishment of our company
- 2000
-
Established Innovacell Biotechnologie GmbH in Innsbruck, Austria.
- 2005
-
Obtained GMP certification for our manufacturing facility.
- 2008
-
Changed corporate structure (from Innovacell Biotechnologie GmbH to Innovacell Biotechnologie AG).
- 2011
-
Completed Phase IIb clinical trial for the autologous skeletal muscle-derived cell product (ICES13) targeting stress urinary incontinence.
- 2016
-
Completed Phase IIb clinical trial for the autologous skeletal muscle-derived cell product (ICEF15) targeting urgency fecal incontinence.
- 2019
-
Major shareholders changed (from a structure centered around European institutional investors to one centered around our directors).
- 2021
-
Implemented a triangular merger, becoming a wholly-owned subsidiary and changing the company name to Innovacell AG.
- 2022
-
Initiated patient enrollment in Europe for the international Phase III clinical trial of the autologous skeletal muscle-derived cell product (ICEF15) targeting fecal incontinence.
-
Administered the product to the first patient in the international Phase III clinical trial of the autologous skeletal muscle-derived cell product (ICEF15) targeting fecal incontinence.
Company History
- 2021
-
Established our company (Inovacell Co., Ltd.) with a capital of 20 million yen.
-
Became the wholly-owned parent company of Innovacell AG through a triangular merger.
- 2022
-
Submitted an application for clinical trials to conduct patient enrollment in Japan for the international Phase III trial of the autologous skeletal muscle-derived cell product (ICEF15) targeting fecal incontinence.
- 2023
-
Initiated patient enrollment in Japan for the Phase III trial of the autologous skeletal muscle-derived cell product (ICEF15) targeting fecal incontinence.
-
Administered the first investigational product to patients enrolled from Japan in the Phase III trial of the autologous skeletal muscle-derived cell product (ICEF15) targeting fecal incontinence.
Management Team
-
Representative Director, Co-CEO
Colin Lee Novick
Colin`s expertise in the field of regenerative medicine is diverse, and he has extensive experience in executing both domestic and international projects in this area, leading them to success.
Representative Director, Co-CEO
Colin Lee Novick
-
Representative Director, Co-CEO
Jason Sieger
In particular, Jason has extensive management and operational experience in the fields of cell products and finance, and he is well-versed in various functions necessary for a biotechnology venture.
Representative Director, Co-CEO
Jason Sieger
-
Director and CSO
Rainer Marksteiner
He is a the scientific founder involved in all core elements of Inovacell, including patents, preclinical and clinical development, and GMP manufacturing facilities.
Director and CSO
Rainer Marksteiner
-
Director
Yasushi Hosono
Achieved IPOs at three companies (including two global filings). He is a well-rounded executive with experience as a CFO of a publicly listed company in the field of regenerative medicine, embodying the trifecta of 'IPO x CFO x regenerative medicine.
Director
Yasushi Hosono
